anti-miR-33 antisense oligonucleotide (Regulus/New York University/AstraZeneca)

N/A

Report date: 2025/03/18 20:00:05
NME

Base Information

Drug Nameanti-miR-33 antisense oligonucleotide (Regulus/New York University/AstraZeneca)
Drug Alias Nameanti-miR-33 antisense oligonucleotide (Regulus/New York University)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > microRNASmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionAntisense oligonucleotide inhibitors
TargetsUpdating
Therapy Area/IndicationsMetabolic DiseasesAtherosclerosisCardiovascular Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRegulus Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRegulus Therapeutics IncAstrazeneca PlcNew York University
Active IndicationsN/A
Inactive IndicationsMetabolic DiseasesAtherosclerosisCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A